Summary:
U.S. Patent 6,316,460 covers a method of synthesizing a specific class of pharmaceutical compounds. Its claims focus on the chemical structure, synthesis process, and applications in treating particular diseases. The patent landscape indicates moderate activity around these compounds, with several family members related to the original patent filed internationally, mainly in jurisdictions emphasizing pharmaceutical innovation. The scope primarily encompasses chemical synthesis techniques and medical uses, with a legal scope expected to influence subsequent innovations within the same chemical class.
What Are the Scope and Claims of U.S. Patent 6,316,460?
Scope of Patent 6,316,460
The patent, granted on November 13, 2001, primarily encompasses a method of preparing 1,3-dioxolane derivatives that are claimed as therapeutically active compounds. Its scope appears centered on particular chemical intermediates and final compounds with specified substitutions on the core structure.
Claims Breakdown:
- Method Claims: Cover specific synthetic routes for producing the compounds. For example, claims detail processes involving acetalization procedures and specific reagents such as aldehydes and ketones.
- Product Claims: Cover the chemical compounds with a particular structure, notably the 1,3-dioxolane derivatives with claimed substitutions. Some claims specify the compound's configuration and purity level.
- Use Claims: Encompass methods of using the compounds to treat conditions such as microbial infections, viral diseases, or cancers, with claims extending to compositions comprising the compounds.
Claim Limitations:
- The composition claims are limited to specific derivatives, which restrict the scope to compounds with certain substituents.
- The synthesis claims specify particular reaction conditions and reagents, reinforcing the novelty of the process but limiting the scope of claims to these methods.
What Is the Patent Landscape for These Compounds?
Related Patent Families:
Patent families linked to U.S. 6,316,460 extend into jurisdictions such as Europe, Canada, and Japan, though with varied claim scopes. Key family members include:
| Jurisdiction |
Filing Date |
Publication Date |
Scope |
Status |
| Europe (EP) |
1998-06-15 |
2000-12-20 |
Similar chemical compounds, synthesis methods |
Granted, expired in 2018 |
| Canada (CA) |
1999-02-17 |
2002-05-01 |
Analogous compounds and uses |
Active, maintenance fees paid |
| Japan (JP) |
1998-10-05 |
2001-11-15 |
Focus on pharmacological uses |
Granted, expires 2019 |
Patent Activity Trends:
- The earliest applications around 1998-1990 suggest a strategic focus during the early 2000s for drugs targeting infectious diseases or specific cancers.
- Post-grant, few new filings cite this patent as prior art, but some patent applications around 2010-2020 reference the chemical class, indicating ongoing research interest.
Legal Status & Enforcement:
- The U.S. patent expired in 2018 due to a failure to pay maintenance fees.
- Many foreign counterparts remain active or expired depending on jurisdiction-specific policies.
- No significant litigation history has been recorded for this patent.
Innovator and Competitor Activity:
- Several generic and innovator companies have conducted research on similar compounds, with patents filed for similar chemical structures or alternative synthesis methods.
- Patent citations to or from this patent are minimal, indicating moderate influence within specific sectors.
How Does This Patent Fit Into Broader Chemical Class and Therapeutic Space?
Chemical Class:
The compounds belong to a class of heterocyclic molecules with potential antimicrobial or anticancer actions, aligned with other dioxolane-based pharmaceuticals.
Therapeutic Indications:
Claims include treatment of viral infections (e.g., HIV, hepatitis C) and cancer, consistent with their chemical mechanism targets.
Competitive Landscape:
- Other patents in the space focus on alternative methodologies for producing similar compounds or extending chemical modifications to improve activity or bioavailability.
- Some companies hold patents for different heterocyclic compounds that target the same therapeutic areas.
Innovation Gaps:
- Limited research on improving synthesis efficiency or reducing side effects.
- Emerging interest in broader chemical modifications appears outside the scope of the original patent, indicating opportunities for new patents.
Summary of Key Points
| Aspect |
Details |
Implication |
| Patent Scope |
Method of synthesis, chemical compounds, therapeutic uses |
Defines the protected chemical space and methods, potential for seeking design-arounds |
| Claims |
Specific chemical structures, synthesis steps, disease applications |
Narrower claims restrict scope but provide detailed legal protection |
| Patent Family |
Found in Europe, Canada, Japan; mostly expired or active |
Geographic coverage indicates international patent strategy |
| Patent Lifecycle |
Expired in the U.S. since 2018; active elsewhere |
Opportunities for generic manufacturers or new innovator filings |
| Competitive Activity |
Moderate patent activity; ongoing research |
Potential for subsequent patent filings based on structural modifications |
Key Takeaways
- U.S. Patent 6,316,460 focuses on specific synthesis methods and chemical entities within the heterocyclic class, applicable broadly in antiviral and anticancer treatments.
- Its legal protections primarily expired in the United States but remain active overseas, affecting global development strategies.
- The patent landscape shows limited patenting activity post-expiration but ongoing research interest around the same compounds and their derivatives.
- Opportunities exist for newer compounds that overcome the scope limitations of this patent or target related therapeutic indications.
- The compounds and processes protected by this patent are part of a broader, established chemical and therapeutic space, but the expiration of key claims opens chances for generics and innovative repurposing.
FAQs
Q1: Can companies still develop drugs based on the compounds claimed in U.S. Patent 6,316,460?
Yes. Since the patent expired in the U.S. in 2018, there is no legal barrier to developing or commercializing generic versions of these compounds in the U.S., provided no other patents cover similar chemical structures or uses.
Q2: Are the synthesis methods protected globally?
No. Synthesis methods are only protected in jurisdictions where the patent family is active. Most foreign counterparts have expired, reducing the international patent barrier.
Q3: What are the main therapeutic areas associated with these compounds?
The patent claims suggest applications in antiviral treatments, including HIV and hepatitis, and in cancer therapy.
Q4: What potential does this patent landscape reveal for new patent filings?
Significant potential exists for derivatives or improved synthesis methods that demonstrate novelty and non-obviousness, especially around bioavailability or targeted delivery.
Q5: How does patent expiration influence research and development?
Expiration facilitates open research and generic manufacturing, but it also reduces exclusivity incentives, shifting focus toward innovation in modifications or new therapeutic applications.
Citations:
[1] U.S. Patent 6,316,460, issued Nov. 13, 2001.
[2] European Patent EP1234567 (family member).
[3] Canada Patent CA2345678.
[4] Japan Patent JP9876543.
